Welcome to Pharmaxis
Pharmaxis is a research-based specialist pharmaceutical company with a portfolio of products at various stages of development and approval.
Phase 1 clinical trial for SSAO/VAP-1 inhibitor commences
Pharmaxis today announced that it has commenced a Phase 1 clinical trial of its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor (PXS4728A) investigating its potential to treat inflammatory diseases.
Pharmaxis releases interim results for phase I clinical trial of SSAO/VAP-1 inhibitor PXS4728A
Pharmaxis has announced positive interim results from the single ascending dose stage of the Phase 1 clinical trial for its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor PXS4728A.
Significant business milestones: Commercialisation of Bronchitol (Mannitol) in USA, Novaquest dispute settled
Pharmaxis announced it has entered into an exclusive distribution and supply agreement with global pharmaceutical company Chiesi Farmaceutici SpA (Chiesi) for the commercialisation of Bronchitol® (mannitol) in the United States.
Pharmaxis signs agreement with Boehringer Ingelheim for SSA Inhibitor PXS4728A
Pharmaxis has announced it has signed an Option and Asset Purchase Agreement with Boehringer Ingelheim for the SSAO Inhibitor PXS4728A.
LATEST NEWS & PUBLICATIONS